New hope for transplant patients: diabetes drugs may fight fatty liver
NCT ID NCT05042505
Summary
This study compared two diabetes medications, dapagliflozin and sitagliptin, in 100 patients with diabetes who had undergone a liver transplant. Researchers wanted to see which drug was better at reducing fat buildup in the liver and improving body composition over 12 months. The goal was to find safer, more effective ways to manage diabetes and its complications in this vulnerable group of patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Division Of Endocrinology & Diabetes, Medanta The Medicity
Gurgaon, Haryana, 122001, India
Conditions
Explore the condition pages connected to this study.